William Blair Issues Negative Forecast for VTGN Earnings

VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Equities research analysts at William Blair dropped their Q1 2026 earnings per share estimates for shares of VistaGen Therapeutics in a research note issued on Wednesday, June 18th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.44) per share for the quarter, down from their prior forecast of ($0.32). William Blair has a "Outperform" rating on the stock. The consensus estimate for VistaGen Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for VistaGen Therapeutics' Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.26) EPS and FY2027 earnings at ($1.69) EPS.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.09. The business had revenue of ($0.01) million for the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative return on equity of 58.88% and a negative net margin of 6,777.08%. During the same quarter in the previous year, the company posted ($0.25) EPS.

VistaGen Therapeutics Stock Down 2.9%

Shares of VTGN stock opened at $2.00 on Monday. The firm has a market capitalization of $58.32 million, a P/E ratio of -1.20 and a beta of 0.70. VistaGen Therapeutics has a twelve month low of $1.90 and a twelve month high of $4.21. The stock's fifty day simple moving average is $2.31 and its 200 day simple moving average is $2.56.

Institutional Investors Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in VistaGen Therapeutics by 4,826,425.0% during the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock worth $2,278,000 after acquiring an additional 772,228 shares during the last quarter. Nantahala Capital Management LLC grew its position in shares of VistaGen Therapeutics by 30.6% in the 4th quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company's stock valued at $5,847,000 after buying an additional 464,284 shares during the last quarter. Almitas Capital LLC bought a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at about $751,000. Blair William & Co. IL grew its position in shares of VistaGen Therapeutics by 11.3% in the 4th quarter. Blair William & Co. IL now owns 98,466 shares of the company's stock valued at $290,000 after buying an additional 10,000 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of VistaGen Therapeutics by 52.9% in the 4th quarter. Millennium Management LLC now owns 38,732 shares of the company's stock valued at $114,000 after buying an additional 13,395 shares during the last quarter. Institutional investors own 78.39% of the company's stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.